King Charles Shakes Hands, Chats with Crowd at Most Significant Public Outing Since Cancer Diagnosis

File photo: Britain's King Charles leaves the London Clinic after receiving treatment for an enlarged prostate, in London, Britain January 29, 2024. (Reuters)
File photo: Britain's King Charles leaves the London Clinic after receiving treatment for an enlarged prostate, in London, Britain January 29, 2024. (Reuters)
TT

King Charles Shakes Hands, Chats with Crowd at Most Significant Public Outing Since Cancer Diagnosis

File photo: Britain's King Charles leaves the London Clinic after receiving treatment for an enlarged prostate, in London, Britain January 29, 2024. (Reuters)
File photo: Britain's King Charles leaves the London Clinic after receiving treatment for an enlarged prostate, in London, Britain January 29, 2024. (Reuters)

King Charles III shook hands and chatted with onlookers after attending an Easter service at Windsor Castle on Sunday in his most significant public outing since being diagnosed with cancer last month.

The king, dressed in a dark overcoat and shiny blue tie, smiled as he made his way along a rope line outside St. George's Chapel for about five minutes, reaching into the crowd to greet supporters who waved get-well cards and snapped photos on a chilly early spring day.  

“You’re very brave to stand out here in the cold,” Charles told them.

“Keep going strong,” one member of the crowd shouted as Charles and Queen Camilla walked by.

The 75-year-old monarch’s appearance was seen as an effort to reassure the public after Charles stepped back from public duties in early February following an announcement by Buckingham Palace that he was undergoing treatment for an unspecified type of cancer.

The king has continued fulfilling his state duties, such as reviewing government papers and meeting with the prime minister. But his attendance at a traditional royal event like the Easter service is seen as a sign that he is beginning a managed return to public life. British media reported last week that Charles would slowly increase his public appearances after Easter.

The service itself was smaller than usual as Kate, the Princess of Wales, is also being treated for cancer and has paused public duties. The princess, her husband Prince William and their children did not attend.

Kate shock’s announcement that she, too, had cancer was made on March 22, after weeks of speculation about her health and whereabouts following major abdominal surgery in February.

Charles’ enforced absence from public life has been a setback for a man who is eager to put his stamp on the monarchy after waiting almost 74 years — longer than any previous heir — to become king.

When he succeeded his mother, Queen Elizabeth II, Charles faced the daunting task of demonstrating that the 1,000-year-old monarchy remains relevant in a modern nation whose citizens come from all corners of the globe. After less than two years on the throne, the king is still defining himself with the public as he tries to persuade young people and members of minority communities that the royal family can represent them.

“He knows that being seen by the public and having public goodwill is really what's at the core of a successful monarchy,” royal commentator Jennie Bond told the BBC. “He needs to have that interaction and I think he quite enjoys it, actually.”

Although the duties of a constitutional monarch are largely ceremonial, the job of being a royal can be exhausting.

Besides the occasional procession in full royal regalia, there are meetings with political leaders, dedication ceremonies and events honoring the accomplishments of British citizens. That added up to 161 days of royal engagements during Charles’s first year on the throne.

The palace has worked hard to keep the king in the public eye — even as he sought to limit contacts to reduce his risk of infection while receiving treatment. Videos of the king reading get-well cards and an audience with Prime Minister Rishi Sunak were released. He also attended a session of the Privy Council, an assembly of senior advisers.

While he skipped a pre-Easter service on Thursday, Charles released a prerecorded audio message in which he expressed his regret at missing an occasion traditionally attended by the monarch.

The king also reaffirmed his coronation pledge “not to be served, but to serve.”

“That I have always tried to do and continue to do, with my whole heart,” he said.



Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”